Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 17/20 | 0.62 |
| ▸ | HTR2B | P41595 | 6/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.57 |
| ▸ | HTR2A | P28223 | 15/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7082838 | 0.84 | HTR2C (0.70) | HTR2CHTR2BCYP1A2HTR2ANPC1 | |
| SCHEMBL7042581 | 0.77 | HTR2C (1.00) | HTR2CHTR2BCYP1A2HTR2A | |
| SCHEMBL7079712 | 0.73 | HTR2C (0.77) | HTR2CHTR2BCYP1A2HTR2ANPC1 | |
| SCHEMBL7042867 | 0.73 | HTR2C (1.00) | HTR2CHTR2BCYP1A2HTR2A | |
| SCHEMBL7040490 | 0.69 | USP2 (0.55) | HTR2CHTR2BCYP1A2HTR2ANPC1 | |
| SCHEMBL7082666 | 0.69 | HTR2C (0.46) | HTR2CHTR2BCYP1A2HTR2ANPC1 | |
| SCHEMBL5871063 | 0.69 | NOTUM (0.66) | MAPTPKMSMN1; SMN2 | |
| SCHEMBL8526818 | 0.69 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL8526790 | 0.68 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL8526238 | 0.68 | HTR2C (1.00) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6638953-B2 | Central nervous system disorders; anxiety | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-28 | — | — | US | disclosed |
| US-20030105139-A1 | Indole derivatives as 5-HT receptor antagonist | SMITHKLINE BEECHAM P.L.C. | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105139-A1 | Indole derivatives as 5-HT receptor antagonist | HTR5A, HTR2C, HTR1A | HTR2C 2/4885HTR2B 11/4885CYP1A2 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.